Arabic Arabic English English French French German German
dark

Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

Today, Akston Biosciences Corporation , a developer of new classes of biologic therapeutics announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections

Next Post

What is the evidence on how to improve older adults’ functional abilities at home?

Related Posts
Total
0
Share